Despite many decades of research, pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult cancers to diagnose and treat effectively. Although there have been improvements in the 5-year overall survival rate, it is still very low at 12.5%. The limited efficacy of current therapies, even when PDAC is detected early, underscores the aggressive nature of the disease and the urgent need for more effective treatments. Clinical management of PDAC still relies heavily on a limited repertoire of therapeutic interventions, highlighting a significant gap between research efforts and available treatments. Over 4300 clinical trials have been or are currently investigating different treatment modalities and diagnostic strategies for PDAC, including targeted therapies, immunotherapies, and precision medicine approaches. These trials aim to develop more effective treatments and improve early detection methods through advanced imaging techniques and blood-based biomarkers. This review seeks to categorize and analyze PDAC-related clinical trials across various dimensions to understand why so few chemotherapeutic options are available to patients despite the numerous trials being conducted. This review aims to provide a comprehensive and nuanced understanding of the landscape of PDAC-related clinical trials, with the overarching goal of identifying opportunities to accelerate progress in drug development and improve patient outcomes in the fight against this devastating disease.
尽管经过数十年的研究，胰腺导管腺癌（PDAC）仍然是诊断和治疗最为困难的癌症之一。虽然五年总生存率有所提高，但仍处于12.5%的极低水平。即便在早期发现的情况下，现有疗法的有限疗效仍凸显了该疾病的侵袭性特征，以及对更有效治疗手段的迫切需求。目前PDAC的临床管理仍严重依赖有限的治疗干预手段，这凸显了研究进展与可用治疗方案之间的显著差距。已有超过4300项临床试验正在或曾经针对PDAC的不同治疗模式和诊断策略展开研究，包括靶向治疗、免疫疗法和精准医疗方法。这些试验旨在通过先进成像技术和血液生物标志物开发更有效的治疗方案并改进早期检测方法。本综述试图从多个维度对PDAC相关临床试验进行分类分析，以探究为何在大量临床试验开展的情况下，患者可用的化疗方案仍然稀缺。通过系统梳理PDAC临床试验的全景图，本综述旨在为加速药物研发进程、改善患者预后提供全面而深入的理解，从而为抗击这一致命疾病寻找突破方向。
Unveiling the Promise: Navigating Clinical Trials 1978–2024 for PDAC
肿瘤(癌症)患者之家